With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.
Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches
While prominent physicians can provide companies with valuable guidance during development, their perspective is limited when it comes to projecting how well or how readily a...
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
The Swiss drugmaker Roche on Tuesday presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval for...
SAN DIEGO — Revolution Medicines is already cooking up the next iteration of RAS inhibiting drugs. At the American Association of Cancer Research annual meeting here,...
WASHINGTON — Both Democratic and Republican Senators who oversee federal spending seemed skeptical of proposed cuts to health research and public health in the White House’s...
The Centers for Medicare and Medicaid Services has delayed a key pilot program focused on Medicare coverage for obesity medications, after insurance plans indicated they wouldn’t...
As the body ages, cells naturally accumulate dozens of genetic mutations each year. New research reported by researchers at Boston Children’s Hospital suggests that the brain’s...
China is “eating our lunch” on new drug approvals and clinical trial starts, HHS Secretary Robert F. Kennedy Jr. told Congress Tuesday, while praising the FDA’s...